In medical contexts, IGT most commonly stands for impaired glucose tolerance, a condition where blood sugar levels are higher than normal but not yet high enough to qualify as type 2 diabetes. It falls under the broader category of prediabetes. A less common use of the abbreviation refers to image-guided therapy, a set of surgical techniques that use imaging technology during procedures. This article focuses on impaired glucose tolerance, since that’s what most people searching “IGT medical” need to understand.
How IGT Is Defined and Diagnosed
Impaired glucose tolerance is diagnosed with an oral glucose tolerance test, often called an OGTT. You drink a solution containing 75 grams of glucose, then have your blood drawn two hours later. If your blood sugar at that two-hour mark falls between 140 and 199 mg/dL, you have IGT. Below 140 mg/dL is considered normal, and 200 mg/dL or above indicates type 2 diabetes.
This is different from another prediabetic condition called impaired fasting glucose (IFG), which is diagnosed based on blood sugar after an overnight fast. A fasting glucose of 100 to 125 mg/dL qualifies as IFG. You can have one without the other, or both at the same time. Having both together may signal more advanced metabolic dysfunction and a greater likelihood of progressing toward diabetes.
What’s Happening in Your Body
IGT results from two overlapping problems. First, your cells become less responsive to insulin, the hormone that helps move sugar from your blood into your tissues. This is called insulin resistance. Second, your pancreas can’t produce enough extra insulin to compensate for that resistance. The balance between these two issues varies from person to person, and genetics play a role in determining how much each factor contributes.
In someone with normal glucose tolerance, the pancreas ramps up insulin production when blood sugar rises after a meal, keeping levels in a healthy range. With IGT, that system is strained. Your body still manages fasting blood sugar reasonably well, which is why IGT specifically shows up after a glucose challenge rather than on a simple fasting blood test.
Symptoms Are Rare but Not Absent
IGT is often described as a “silent” condition because it typically doesn’t cause obvious symptoms. It can go undetected for years, which is one reason screening matters for people with risk factors like obesity, a family history of diabetes, or a history of gestational diabetes.
That said, research involving people living with IGT has found that many do report subtle symptoms when asked directly. One qualitative study identified more than 25 different symptoms across seven categories that people with IGT described experiencing. These are the kinds of vague sensations, like fatigue or feeling “off” after meals, that are easy to dismiss individually but may form a pattern. The challenge is that these perceptions don’t fit neatly into a diagnostic checklist, so they often go unrecognized by both patients and clinicians.
Risk of Progressing to Type 2 Diabetes
IGT is not just a warning label. It carries real, measurable risk. Roughly 40 to 50% of people with IGT will eventually develop type 2 diabetes over their lifetime. The annual progression rate varies widely depending on the population studied, ranging from about 2.3% to 11% per year. In the U.S. Diabetes Prevention Program, which enrolled people with IGT who also had additional risk factors, the conversion rate was approximately 11% per year in the control group.
Even among people who successfully lose weight and improve their habits, 40 to 50% still progress to diabetes. That statistic underscores that lifestyle changes are powerful but not a guarantee, particularly for those with strong genetic predisposition. In the United States, an estimated 41 million people have IGT, making it a substantial public health concern.
Cardiovascular Risk Starts Early
One of the most important things to understand about IGT is that the damage to your cardiovascular system doesn’t wait for a diabetes diagnosis. People with IGT already face an elevated risk of heart disease. Even blood sugar levels in the upper-normal range, not yet crossing the IGT threshold, are associated with increased cardiovascular risk.
Research has shown that the risk of heart disease can begin increasing as early as 15 years before someone is formally diagnosed with diabetes. Patients hospitalized for acute heart events like heart attacks frequently turn out to have previously undiagnosed IGT or diabetes when tested. This means IGT isn’t just a stepping stone to diabetes. It’s a cardiovascular risk factor in its own right.
Managing IGT With Lifestyle Changes
The primary approach to managing IGT focuses on two targets: weight loss of 5 to 7% of body weight and at least 150 minutes per week of moderate-intensity physical activity. That’s about 30 minutes of brisk walking five days a week. Clinical trials have also highlighted the value of reducing dietary fat intake and increasing fiber consumption as part of a broader eating pattern shift.
These numbers aren’t arbitrary. They come from large prevention trials that demonstrated significant reductions in the rate of progression to diabetes. For someone weighing 200 pounds, a 5 to 7% loss means shedding 10 to 14 pounds, a realistic goal that produces measurable metabolic benefits. The combination of moderate exercise and modest weight loss improves both insulin sensitivity and the pancreas’s ability to respond to blood sugar spikes.
IGT as Image-Guided Therapy
In radiology and surgical contexts, IGT can also stand for image-guided therapy. This refers to the use of medical imaging, most commonly MRI or CT scans, to plan, perform, and evaluate surgical procedures or other therapeutic interventions. The concept covers everything from making traditional surgeries more precise to performing minimally invasive procedures on internal organs without a surgical incision. The FDA approved the first image-guided procedure in 2004: MRI-guided focused ultrasound for treating uterine fibroids. The technique has since expanded to treat brain tumors, breast tumors, and pain from cancer that has spread to bone.